Antitumor effect of bevacizumab in a xenograft model of canine hemangiopericytoma

Journal of Pharmacological Sciences

Volumn 121, Issue 4, 2013, Pages 339-342

  Michishita, Masaki ^a   Uto, Tatsuya ^a   Nakazawa, Ryota ^a   Yoshimura, Hisashi ^a   Ogihara, Kikumi ^b   Naya, Yuko ^b   Tajima, Tsuyoshi ^a   Azakami, Daigo ^a   Kishikawa, Seigo ^b   Arai, Toshiro ^a   Takahashi, Kimimasa ^a  

^a NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^b AZABU UNIVERSITY   (Japan)

Author keywords

Bevacizumab; Canine hemangiopericytoma; Vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; HEMANGIOPERICYTOMA; MALE; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

EID: 84877616618     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12268SC     Document Type: Article

References (15)

1. Graves GM, Bjorling DE, Mahaffey E. Canine hemangiopericytoma: 23 cases (1967-1984). J Am Vet Med Assoc. 1998; 192:99-102.
2. Postorino NC, Berg RJ, Powers EB, McChesney AE, Taylor RA, Withrow SJ. Prognostic variables for canine hemangiopericytoma: 50 cases (1974-1984). J Am Anim Hosp Assoc. 1988;24:501-509.
3. Goldschmidt MH, Hendrick MJ. Tumors of the skin and soft tissues. In: Meuten, editor. Tumors of Domestic Animals. 4 th ed. Ames: Iowa State Press; 2002. p. 94-95.
4. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic swich. Nat Rev Cancer. 2003;3:401-410.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
6. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-255.
8. de Queiroz GF, Dagli ML, Fukumasu H, Zavala AA, Matera JM. Vascular endothelial growth factor expression and microvascular density in soft tissue sarcomas in dogs. J Vet Diagn Invest. 2010;22:105-108.
9. Restucci B, Papparella S, Maiolino P, de Vico G. Expression of vascular endothelial growth factor in canine mammary tumors. Vet Pathol. 2002;39:488-493.
10. Ogihara K, Miyatake S, Kishikawa S, Tsuchiya T, Kuroda Y. A transplanted and cultured cell line established from canine malignant hemangiopericytoma and its immunohistochemical characterization. Tiss Cult Res Commun. 1999;18:291-300.
11. Fujita K, Sano D, Kimura M, Yamashita Y, Kawakami M, Ishiguro Y, et al. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep. 2007;18:47-51.
12. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer. 2002;86:1566-1577.
13. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A. 1997;94:7192-7197.
14. Mizobe T, Ogata Y, Murakami H, Akagi Y, Ishibashi N, Mori S, et al. Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma. Oncol Rep. 2008;20:517-523.
15. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 2009;8:1867-1877.